Results 191 to 200 of about 133,285 (252)

Novel recombinant human adenoviruses: A call for enhanced molecular surveillance, diagnosis, and management in pediatric acute respiratory infections

Pediatric Investigation, EarlyView.
Zhen Zhu, Naiying Mao
wiley   +1 more source

Time‐Resolved Multi‐Omics Identify Biomarkers of Immediate Reactions to mRNA Vaccination

Allergy, EarlyView.
We compared early vaccine‐induced immune and metabolic signatures and downstream immunity after second and booster BNT162b2 doses in participants with sARs, ISSRs, or no reactions. Neutrophil mobilization, antiviral programs, and robust anti‐S‐antibody responses occurred across reaction groups.
Ana Olivera, Benjamin Schwarz, Brittany Dulek, Ian S. LaCroix, Min Li, Lindsay Chatman, Muhammad B. Khalid, Ellen Zektser, Karen Laky, Stella Hartono, Eric Bohrnsen, Cole D. Kimzey, Eric Chu, Roa Harb, Pamela A. Frischmeyer‐Guerrerio   +14 more
wiley   +1 more source

Advances in the development of a vaccine for the prevention of human leptospirosis: a review. [PDF]

Rev Inst Med Trop Sao Paulo
Jesus MS, Almeida MEM, Mariúba LAM.
europepmc   +1 more source

Pre‐Seasonal Treatment With Recombinant Carrier‐Based Birch Vaccine Improves Birch Pollen Allergy

Allergy, EarlyView.
We conducted a two stage SCIT trial with GNR‐127 containing a recombinant fusion protein consisting of Bet v 1 and Mal d 1‐derived peptides fused to PreS from HBV. Stage 1 identified two safe maximum tolerated doses (40 μg and 80 μg). In the following Stage 2, five preseasonal injections were well tolerated, induced dose‐dependent allergen‐specific IgG,
Musa R. Khaitov, Maria G. Byazrova, Evgenii V. Smolnikov, Vladislav N. Turenko, Valeriy V. Smirnov, Igor P. Shilovskii, Nadezhda N. Shershakova, Ekaterina N. Medunitsyna, Olga G. Elisyutina, Mikhail V. Pashenkov, George B. Pasikhov, Vladimir V. Murugin, Veronika A. Parshina, Darya K. Bolyakina, Anastasia S. Primak, Mariya A. Lapyko, Inna V. Danilycheva, Rosalia V. Schubelko, Anastasia A. Tsyvkina, Nataliia V. Shartanova, Daria O. Timoshenko, Irina I. Isakova, Tatiana V. Latysheva, Andrey E. Shulzhenko, Elena A. Latysheva, Oksana M. Kurbacheva, Elena S. Fedenko, Oksana A. Markova, Ilya A. Korotkevich, Violetta V. Yan, Natalia A. Gavrilova, Mariia V. Tikhomirova, Ivan V. Shevchenko, Alena A. Agafonova, Gregory N. Poroshin, Dmitry A. Kudlay, Alexander V. Filatov, Evgeniya V. Nazarova, Daria S. Kruchko, Dmitriy V. Goryachev, Vadim A. Merkulov, Nataliya I. Ilina, Rudolf Valenta, Veronica I. Skvortsova   +43 more
wiley   +1 more source

CD4+ T-cell immunity to <i>Bordetella pertussis</i>. [PDF]

Discov Immun
Hall JM, Defalco JB, Dubey P.
europepmc   +1 more source

Whole-genome sequencing and molecular characterization of Newcastle disease virus isolates from Kazakhstan. [PDF]

Front Vet Sci
Nurpeisova A, Zheney M, Akshalova P, Ikramkulova F, Begassyl K, Nissanova R, Mamanova S, Serikov M, Ibraim N, Koshkinbay N, Zholdasbekova A, Yoo HS, Kassenov M, Abay Z.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Promising whole‐cell vaccines against cryptococcosis

Microbiology and Immunology, 2023
AbstractCryptococcosis is a mycosis caused by Cryptococcus neoformans and C. gattii species complexes. Although this infection is potentially lethal, no prophylactic vaccine is yet commercially available, and the immune memory that enables prevention is still under investigation.
Keigo Ueno, Soichiro Tsuge, Kiminori Shimizu, Yoshitsugu Miyazaki   +3 more
openaire   +2 more sources

Whole-Cell and Acellular Pertussis Vaccines

Annals of Pharmacotherapy, 1994
OBJECTIVE: To provide a review of pertussis vaccines, including information on efficacy, adverse reactions, and antibody production following administration of both whole-cell and acellular pertussis vaccines. DATA SOURCES: A MEDLINE ...
S M, Wintermeyer, M C, Nahata, K S, Kyllonen   +2 more
openaire   +2 more sources